A Single-center Retrospective Study of MIAD ± R Chemotherapy in Newly Diagnosed Primary Central Nervous System Lymphoma: Safety Profiles and Clinical Outcomes. (PubMed, Clin Lymphoma Myeloma Leuk) - Sep 25, 2026 - "The MIAD ± R regimen is a viable treatment option for newly diagnosed PCNSL with favorable efficacy and an acceptable safety profile. Further prospective trials are warranted to verify its value in the first-line standard of treatment in PCNSL."
Clinical data • Journal • Retrospective data • CNS Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Non-Hodgkin's Lymphoma • Oncology • Primary Central Nervous System Lymphoma
|
|
Huixiu Han; Jing Liu; Jun Qian; Lin Fu; Qing Liu; Qu Cui; Ruixian Xing; Wenyuan Lai; Xuefei Sun; Xueyan Bai; Yuanbo Liu; Yuchen Wu; Yuedan Chen
|